Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom; National Center for Scientific Research "Demokritos," Aghia Paraskevi, Greece.
Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom.
Fertil Steril. 2013 Jan;99(1):76-85. doi: 10.1016/j.fertnstert.2012.08.035. Epub 2012 Sep 21.
To determine the effect of infertility-linked sperm phospholipase Cζ (PLCζ) mutations on their ability to trigger oocyte Ca(2+) oscillations and development, and also to evaluate the potential therapeutic utility of wild-type, recombinant PLCζ protein for rescuing failed oocyte activation and embryo development.
Test of a novel therapeutic approach to male factor infertility.
University medical school research laboratory.
PATIENT(S): Donated unfertilized human oocytes from follicle reduction.
INTERVENTION(S): Microinjection of oocytes with recombinant human PLCζ protein or PLCζ cRNA and a Ca(2+)-sensitive fluorescent dye.
MAIN OUTCOME MEASURE(S): Measurement of the efficacy of mutant and wild-type PLCζ-mediated enzyme activity, oocyte Ca(2+) oscillations, activation, and early embryo development.
RESULT(S): In contrast to the wild-type protein, mutant forms of human sperm PLCζ display aberrant enzyme activity and a total failure to activate unfertilized oocytes. Subsequent microinjection of recombinant human PLCζ protein reliably triggers the characteristic pattern of cytoplasmic Ca(2+) oscillations at fertilization, which are required for normal oocyte activation and successful embryo development to the blastocyst stage.
CONCLUSION(S): Dysfunctional sperm PLCζ cannot trigger oocyte activation and results in male factor infertility, so a potential therapeutic approach is oocyte microinjection of active, wild-type PLCζ protein. We have demonstrated that recombinant human PLCζ can phenotypically rescue failed activation in oocytes that express dysfunctional PLCζ, and that this intervention culminates in efficient blastocyst formation.
确定与不育相关的精子磷酯酶 Cζ(PLCζ)突变对其触发卵母细胞 Ca(2+)振荡和发育能力的影响,同时评估野生型、重组 PLCζ 蛋白用于挽救卵母细胞激活和胚胎发育失败的潜在治疗用途。
男性因素不育治疗新方法的检验。
大学医学院研究实验室。
来自卵泡减少的未受精的人卵母细胞捐赠。
卵母细胞的重组人 PLCζ 蛋白或 PLCζ cRNA 和 Ca(2+)敏感荧光染料的微注射。
测量突变型和野生型 PLCζ 介导的酶活性、卵母细胞 Ca(2+)振荡、激活和早期胚胎发育的效率。
与野生型蛋白相比,人精子 PLCζ 的突变形式显示出异常的酶活性,并且完全不能激活未受精的卵母细胞。随后,重组人 PLCζ 的微注射可靠地触发了受精时细胞质 Ca(2+)振荡的特征模式,这是正常卵母细胞激活和成功胚胎发育至胚泡阶段所必需的。
功能失调的精子 PLCζ 不能触发卵母细胞激活,导致男性因素不育,因此一种潜在的治疗方法是卵母细胞微注射活性的、野生型 PLCζ 蛋白。我们已经证明,重组人 PLCζ 可以表型挽救表达功能失调 PLCζ 的卵母细胞中的失败激活,并且这种干预最终导致有效的胚泡形成。